Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2008

01.01.2008 | Gastrointestinal Oncology

Activin A Causes Cancer Cell Aggressiveness in Esophageal Squamous Cell Carcinoma Cells

verfasst von: Keiji Yoshinaga, PhD, MD, Keishi Yamashita, PhD, MD, Koshi Mimori, PhD, MD, Fumiaki Tanaka, PhD, MD, Hiroshi Inoue, PhD, MD, Masaki Mori, PhD, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Expression of activin A is associated with lymph node metastasis and clinical stage in esophageal cancer.

Methods

To clarify the aggressive behavior of tumors with high activin A expression, we used the β subunit of activin A to establish stable activin βA (Act-βA)-transfected carcinoma cells in two human esophageal carcinoma cell lines, KYSE110 and KYSE140. The biological behavior of these cells was compared with that in mock-transfected cells from the same cell lines. We focused our attention on cell growth and tumorigenesis, and proliferation and apoptosis.

Results

Both Act-βA–transfected carcinoma cell lines showed a higher growth rate than the mock-transfected carcinoma cells. In an in vitro invasion assay and a xenograft analysis, the Act-βA–transfected carcinoma cells showed far higher proliferation in vitro and a higher potency for tumorigenesis in vivo, respectively. Moreover, in an analysis of apoptosis via Fas stimulation, the Act-βA–transfected carcinoma cells showed a higher tolerance to apoptosis compared with the mock-transfected carcinoma cells. Moreover, anti–activin-neutralizing antibody–treated squamous cell cancer cell lines inhibited their migration.

Conclusions

Collectively, these data indicate that continuous high expression of activin A in esophageal carcinoma cells is not related to tumor suppression, but rather to tumor progression in vitro and in vivo. The inhibition of activin might be one of the methods to attenuate tumor aggressiveness.
Literatur
1.
Zurück zum Zitat Asashima M, Ariizumi T, Malacinski GM. In vitro control of organogenesis and body patterning by activin during early amphibian development. Comp Biochem Physiol B Biochem Mol Biol 2000;126:169–78PubMedCrossRef Asashima M, Ariizumi T, Malacinski GM. In vitro control of organogenesis and body patterning by activin during early amphibian development. Comp Biochem Physiol B Biochem Mol Biol 2000;126:169–78PubMedCrossRef
2.
Zurück zum Zitat Yoshinaga K, Mimori M, Yamashita K, et al. Clinical significance of the expression of activin A in esophageal carcinoma. Int J Oncol 2003;22:75–80PubMed Yoshinaga K, Mimori M, Yamashita K, et al. Clinical significance of the expression of activin A in esophageal carcinoma. Int J Oncol 2003;22:75–80PubMed
3.
Zurück zum Zitat Kleeff J, Ishiwata T, Friess H, et al. Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer. Int J Cancer 1998;77:860–8PubMedCrossRef Kleeff J, Ishiwata T, Friess H, et al. Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer. Int J Cancer 1998;77:860–8PubMedCrossRef
4.
Zurück zum Zitat Thomas TZ, Wang H, Niclasen P, et al. Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer. J Clin Endocrinol Metab 1997;82:3851–8PubMedCrossRef Thomas TZ, Wang H, Niclasen P, et al. Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer. J Clin Endocrinol Metab 1997;82:3851–8PubMedCrossRef
5.
Zurück zum Zitat Woodruff TK. Role of inhibins and activins in ovarian cancer. Cancer Treat Res 2002;107:293–302PubMed Woodruff TK. Role of inhibins and activins in ovarian cancer. Cancer Treat Res 2002;107:293–302PubMed
6.
Zurück zum Zitat Zheng W, Luo MP, Welt C, et al. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol 1998;69:23–31PubMedCrossRef Zheng W, Luo MP, Welt C, et al. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol 1998;69:23–31PubMedCrossRef
7.
Zurück zum Zitat Wildi S, Kleeff J, Maruyama H, Maurer CA, Buchler MW, Korc M. Overexpression of activin A in stage IV colorectal cancer. Gut 2001;49:409–17PubMedCrossRef Wildi S, Kleeff J, Maruyama H, Maurer CA, Buchler MW, Korc M. Overexpression of activin A in stage IV colorectal cancer. Gut 2001;49:409–17PubMedCrossRef
8.
Zurück zum Zitat Petraglia F, Florio P, Luisi S, et al. Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab 1998;83:1194–200PubMedCrossRef Petraglia F, Florio P, Luisi S, et al. Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab 1998;83:1194–200PubMedCrossRef
9.
Zurück zum Zitat Kojima I, Ogata E. Dual effect of activin A on cell growth in Balb/c 3T3 cells. Biochem Biophys Res Commun 1989;159:1107–13PubMedCrossRef Kojima I, Ogata E. Dual effect of activin A on cell growth in Balb/c 3T3 cells. Biochem Biophys Res Commun 1989;159:1107–13PubMedCrossRef
10.
Zurück zum Zitat Rabinovici J, Spencer SJ, Jaffe RB. Recombinant human activin-A promotes proliferation of human luteinized preovulatory granulosa cells in vitro. J Clin Endocrinol Metab 1990;71:1396–8PubMedCrossRef Rabinovici J, Spencer SJ, Jaffe RB. Recombinant human activin-A promotes proliferation of human luteinized preovulatory granulosa cells in vitro. J Clin Endocrinol Metab 1990;71:1396–8PubMedCrossRef
11.
Zurück zum Zitat Di Simone N, Crowley WF Jr, Wang QF, et al. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 1996;137:486–94PubMedCrossRef Di Simone N, Crowley WF Jr, Wang QF, et al. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 1996;137:486–94PubMedCrossRef
12.
Zurück zum Zitat Coerver KA, Woodruff TK, Finegold MJ, et al. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Mol Endocrinol 1996;10:534–43PubMedCrossRef Coerver KA, Woodruff TK, Finegold MJ, et al. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Mol Endocrinol 1996;10:534–43PubMedCrossRef
13.
Zurück zum Zitat Russell CE, Hedger MP, Brauman JN, et al. Activin A regulates growth and acute phase proteins in the human liver cell line, HepG2. Mol Cell Endocrinol 1999;148:129–36PubMedCrossRef Russell CE, Hedger MP, Brauman JN, et al. Activin A regulates growth and acute phase proteins in the human liver cell line, HepG2. Mol Cell Endocrinol 1999;148:129–36PubMedCrossRef
14.
Zurück zum Zitat Cocolakis E, Lemay S, Ali S, Lebrun JJ. The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem 2001;276:18430–6PubMedCrossRef Cocolakis E, Lemay S, Ali S, Lebrun JJ. The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem 2001;276:18430–6PubMedCrossRef
15.
Zurück zum Zitat Yokomuro S, Tsuji H, Lunz JG III, et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 2000;32:26–35PubMedCrossRef Yokomuro S, Tsuji H, Lunz JG III, et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 2000;32:26–35PubMedCrossRef
16.
Zurück zum Zitat Breit S, Ashman K, Wilting J, et al. The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res 2000;60:4596–601PubMed Breit S, Ashman K, Wilting J, et al. The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res 2000;60:4596–601PubMed
17.
Zurück zum Zitat Mori M, Mimori K, Sadanaga N, et al. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in esophageal carcinoma. Int J Cancer 2000;88:575–8PubMedCrossRef Mori M, Mimori K, Sadanaga N, et al. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in esophageal carcinoma. Int J Cancer 2000;88:575–8PubMedCrossRef
18.
Zurück zum Zitat Yamashita K, Mori M, Shiraishi T, et al. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 2000;6:1169–74PubMed Yamashita K, Mori M, Shiraishi T, et al. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 2000;6:1169–74PubMed
19.
Zurück zum Zitat Yoshinaga K, Inoue H, Tanaka F, et al. Platelet-derived endothelial cell growth factor mediates Rho-associated coiled-coil domain kinase messenger RNA expression and promotes cell motility. Ann Surg Oncol 2003;10:582–7PubMedCrossRef Yoshinaga K, Inoue H, Tanaka F, et al. Platelet-derived endothelial cell growth factor mediates Rho-associated coiled-coil domain kinase messenger RNA expression and promotes cell motility. Ann Surg Oncol 2003;10:582–7PubMedCrossRef
20.
Zurück zum Zitat Carcamo J, Weis F, Ventura F, et al. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin. Mol Cell Biol 1994;14:3810–21PubMed Carcamo J, Weis F, Ventura F, et al. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin. Mol Cell Biol 1994;14:3810–21PubMed
21.
Zurück zum Zitat Dennler S, Itoh S, Vivien D, et al. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091–100PubMedCrossRef Dennler S, Itoh S, Vivien D, et al. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091–100PubMedCrossRef
22.
Zurück zum Zitat Docagne F, Nicole O, Marti HH, et al. Transforming growth factor-beta 1 as a regulator of the serpins/t-PA axis in cerebral ischemia. FASEB J 1999;13:1315–24PubMed Docagne F, Nicole O, Marti HH, et al. Transforming growth factor-beta 1 as a regulator of the serpins/t-PA axis in cerebral ischemia. FASEB J 1999;13:1315–24PubMed
23.
Zurück zum Zitat Lloyd RV, Erickson LA, Jin L, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313–23PubMed Lloyd RV, Erickson LA, Jin L, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313–23PubMed
24.
Zurück zum Zitat Jin L, Qian X, Kulig E, et al. Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 1997;151:509–19PubMed Jin L, Qian X, Kulig E, et al. Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 1997;151:509–19PubMed
25.
Zurück zum Zitat Qian X, Jin L, Grande JP, et al. Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 1996;137:3051–60PubMedCrossRef Qian X, Jin L, Grande JP, et al. Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 1996;137:3051–60PubMedCrossRef
26.
Zurück zum Zitat Ling N, Ying SY, Ueno N, et al. A homodimer of the beta-subunits of inhibin A stimulates the secretion of pituitary follicle stimulating hormone. Biochem Biophys Res Commun 1986;138:1129–37PubMedCrossRef Ling N, Ying SY, Ueno N, et al. A homodimer of the beta-subunits of inhibin A stimulates the secretion of pituitary follicle stimulating hormone. Biochem Biophys Res Commun 1986;138:1129–37PubMedCrossRef
27.
Zurück zum Zitat Ling N, Ying SY, Ueno N, et al. Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. Nature 1986;321:779–82PubMedCrossRef Ling N, Ying SY, Ueno N, et al. Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. Nature 1986;321:779–82PubMedCrossRef
28.
Zurück zum Zitat Vale W, Rivier C, Hsueh A, et al. Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 1988;44:1–34PubMed Vale W, Rivier C, Hsueh A, et al. Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 1988;44:1–34PubMed
29.
Zurück zum Zitat Findlay J. An update on the roles of inhibin, activin, and follistatin as local regulators of folliculogenesis. Biol Reprod 1993;48:15–23PubMedCrossRef Findlay J. An update on the roles of inhibin, activin, and follistatin as local regulators of folliculogenesis. Biol Reprod 1993;48:15–23PubMedCrossRef
30.
Zurück zum Zitat Dalkin AC, Gilrain JT, Bradshaw D, et al. Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. Endocrinology 1996;137:5230–5PubMedCrossRef Dalkin AC, Gilrain JT, Bradshaw D, et al. Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. Endocrinology 1996;137:5230–5PubMedCrossRef
31.
Zurück zum Zitat Liu QY, Niranjan B, Gomes P, et al. Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells. Cancer Res 1996;56:1155–63PubMed Liu QY, Niranjan B, Gomes P, et al. Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells. Cancer Res 1996;56:1155–63PubMed
32.
Zurück zum Zitat Zheng W, Sung CJ, Hanna I, et al. Alpha and beta subunits of inhibin/activin as sex cord-stromal differentiation markers. Int J Gynecol Pathol 1997;16:263–71PubMedCrossRef Zheng W, Sung CJ, Hanna I, et al. Alpha and beta subunits of inhibin/activin as sex cord-stromal differentiation markers. Int J Gynecol Pathol 1997;16:263–71PubMedCrossRef
33.
Zurück zum Zitat Yoshinaga K, Inoue H, Utsunomiya T, et al. N-cadherin is regulated by activin A and associated with tumor aggressiveness in esophageal carcinoma. Clin Cancer Res 2004;10:5702–7PubMedCrossRef Yoshinaga K, Inoue H, Utsunomiya T, et al. N-cadherin is regulated by activin A and associated with tumor aggressiveness in esophageal carcinoma. Clin Cancer Res 2004;10:5702–7PubMedCrossRef
34.
Zurück zum Zitat Cavallaro U, Schaffhauser B, Christofori G. Cadherins and the tumour progression: is it all in a switch? Cancer Lett 2002;176:123–8PubMedCrossRef Cavallaro U, Schaffhauser B, Christofori G. Cadherins and the tumour progression: is it all in a switch? Cancer Lett 2002;176:123–8PubMedCrossRef
35.
Zurück zum Zitat Suyama K, Shapiro I, Guttman M, et al. signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002;2:301–14PubMedCrossRef Suyama K, Shapiro I, Guttman M, et al. signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002;2:301–14PubMedCrossRef
Metadaten
Titel
Activin A Causes Cancer Cell Aggressiveness in Esophageal Squamous Cell Carcinoma Cells
verfasst von
Keiji Yoshinaga, PhD, MD
Keishi Yamashita, PhD, MD
Koshi Mimori, PhD, MD
Fumiaki Tanaka, PhD, MD
Hiroshi Inoue, PhD, MD
Masaki Mori, PhD, MD
Publikationsdatum
01.01.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9631-1

Weitere Artikel der Ausgabe 1/2008

Annals of Surgical Oncology 1/2008 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.